Green Cross Health (GXH) AGM Presentation summary
Event summary combining transcript, slides, and related documents.
AGM Presentation summary
15 May, 2026Financial performance highlights
Operating revenue rose 4% to $523.8m, driven by acquisitions and strong pharmacy dispensary performance, partially offset by retail decline.
Operating profit increased to $38.7m, reflecting top line growth and operational improvements.
Net profit after tax attributable to shareholders grew to $16.0m, with EPS at 11.1 cps.
Final FY25 dividend of 2.75 cps declared, with total dividends paid during the year at 7.0 cps.
Gearing ratio at 11.9% and net cash position of $1.8m as of 31 March 2025; $52.6m operating cash flow enabled investments and debt repayment.
Pharmacy division performance and strategy
Pharmacy revenue up 2% to $370.4m, with operating profit rising to $21.5m due to growth and store optimisation.
38 million script items dispensed, with a 4% same-store growth in script items.
Care & Advice Health Hubs expanded, with 77,000 online bookings and 326,000 vaccinations administered.
Beauty by Life concept launched, enhancing in-store experience and product range.
Living Rewards membership exceeded 2.09 million, with members spending 50% more than non-members.
Medical division performance and strategy
Medical revenue up 9% to $153.4m, driven by acquisitions and operational improvements.
Operating profit increased to $19.5m; 416,500 enrolled patients and ownership in 65 medical centres.
Employee costs reduced to 72% of revenue through operational efficiency and technology.
Major refurbishments and rebranding continued, with over 120,000 app users and 16,000 telehealth consults.
Focus on innovative care models, direct funding advocacy, and continuous operational improvement.
Latest events from Green Cross Health
- Revenue up, profit down; network and loyalty programme expanded, with ongoing investments.GXH
AGM Presentation15 May 2026 - Revenue hit $523.8m, net profit $16.0m, and a 2.75c dividend was declared.GXH
H2 202515 May 2026 - Revenue up 2%, profit down 20% as inflation and lower COVID-19 activity hit margins.GXH
H2 202415 May 2026 - Net profit and revenue rose, with medical services leading growth and a higher interim dividend declared.GXH
H1 202627 Nov 2025 - Revenue and profit rose as clinical services, digital innovation, and governance advanced.GXH
AGM 202516 Nov 2025 - Revenue, profit, and cash flow rose, with growth in both Pharmacy and Medical segments.GXH
H1 202513 Jun 2025